AnPac Bio-Medical Science Co Ltd – A.D.R. (NASDAQ: ANPC) recently announced that Mr. Chao Feng has been appointed as an independent director effective July 19, 2021. Mr. Feng, who has previously worked for 2 U.S. Fortune 500 companies in China, will replace the outgoing director, Ms. Lin Yu, who resigned as company director due to personal reasons.
About Mr. Chao
Mr. Chao Feng has served as G.M. of Shanghai Zhiruihaochen Information Technology CO., Ltd since 2019. He has also been the chairman of the strategy committee of Shanghai Leiyi Internet Technology Co. since 2018. In addition, he has held the same position in the strategy committee of Ghuanzhou Chengding Robots Co., Ltd since 2016. Mr. Chao also served as crucial account project director at Hewlett Packard Enterprise Co (NYSE: H.P.E.) China from 2010 to 2012 and data discovery sales manager at Oracle China from 2012 to 2015. Mr. Chao received his bachelor’s degree from Xidian University’s School of Computer Science and Technology and his M.B.A. from East China University of Science and Technology in 2016.
In a press release, Dr. Chris Yu, the C.E.O. and Chairman of the board of directors for Anpac Bio, said that he welcomes Mr. Chao Feng in joining the company’s board of directors. He added that Mr. Chao’s strong academic background and business management experience, especially in strategic planning, capital market transactions, and sales, will become handy for the company in its pursuit of long-term growth. On behalf of the company’s management team, she also thanked Ms. Lin Yu for her contributions.
Mr. Chao’s remarks
Mr. Chao Feng, on the other hand, expressed his excitement by saying that he looks forward to working for the company which has been recognized in the field of early cancer screening and detection. He added that he looks forward to contributing to AnPac Bio’s future success as a member of its board while helping the company further in its development.
AnPAc Bio is a biotechnology company that focuses on early cancer detection and screening with 142 issued patients as of March 31, 2021. The company has two certified laboratories in China, and one CLIA registered clinical lab in the U.S.
